Here Are 3 Medical Supply Stocks to Consider Amid Rising Prospects

Why It Matters

The outlook signals strong earnings upside for investors while underscoring structural demand trends that could reshape dental care delivery and supply‑chain dynamics.

Key Takeaways

• Global medical‑dental supplies market to hit $163.5 B by 2027.
• AI, digital workflows, and aging demographics drive industry growth.
• Zacks Industry Rank #85, forward P/E 17.35×, below S&P 500.
• Cardinal Health, Cooper Companies, Becton Dickinson top stock picks.
• Tariff pressures and regulatory changes pose near‑term risk.

Pulse Analysis

The medical‑dental supplies sector is entering a period of sustained expansion, with the Markets and Markets forecast placing global revenue at $163.5 billion by 2027. A 3.4% compound annual growth rate reflects demographic headwinds—particularly the growing 65‑plus cohort—and a surge in oral‑health awareness that fuels higher procedure volumes. At the same time, AI‑driven diagnostics, CAD/CAM imaging, and digital workflow platforms are reshaping clinical practice, delivering faster turnaround, higher precision, and new revenue streams for consumables and equipment manufacturers.

Investors are zeroing in on three market leaders that stand to benefit most from these macro trends. Cardinal Health (CAH) leverages its dual‑segment model, with pharmaceutical volume gains and a rebound in medical consumables, guiding 2026 adjusted EPS of $10.15‑$10.35 and a projected 16.5% revenue lift. The Cooper Companies (COO) ride growth in premium contact lenses and fertility‑related consumables, targeting $4.58‑$4.66 EPS and 5.6% revenue growth. Becton Dickinson (BDX) has streamlined into a pure‑play med‑tech play, earning recurring consumable revenue while navigating a modest revenue dip; its 2026 EPS outlook sits at $12.35‑$12.65. All three trade at forward P/E multiples below the broader S&P 500, offering relative valuation appeal.

Nevertheless, the industry faces headwinds that could temper optimism. Ongoing U.S. tariff measures inflate the cost of imported dental inputs, squeezing margins and prompting firms to diversify supply chains toward domestic sources. Stricter regulatory scrutiny of AI‑enabled devices adds compliance overhead, while geopolitical tensions affect demand in Asia‑Pacific markets. Investors should weigh these risks against the sector’s growth catalysts, monitoring margin pressure and policy developments as they assess long‑term exposure to medical‑dental supply equities.